This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Alpert, M. A. Articles by Morgan, R. J. Search for Related Content PubMed PubMed Citation Articles by Alpert, M. A. Articles by Morgan, R. J. Social Bookmarking                         What's this?

Efficacy of Betaxolol in the Treatment of Stable Exertional Angina Pectoris: A Dose-Ranging Study

Departments of Medicine, University of Missouri Health Sciences Center and Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

Vaskar Mukerji

Departments of Medicine, University of Missouri Health Sciences Center and Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

Daniel Villarreal

Departments of Medicine, University of Missouri Health Sciences Center and Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

Amolak Singh

Departments of Medicine, University of Missouri Health Sciences Center and Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

Greg C. Flaker

Departments of Medicine, University of Missouri Health Sciences Center and Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

John F. Sanfelippo

Departments of Medicine, University of Missouri Health Sciences Center and Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

C.L. Beach

Departments of Medicine, University of Missouri Health Sciences Center and Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

Rebecca J. Morgan

Departments of Medicine, University of Missouri Health Sciences Center and Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

To assess the efficacy of oral betaxolol in the treatment of stable exertional angina pectoris and to determine the relationship between betaxolol doses/serum concentrations and clinical/hemodynamic responses the authors studied 24 patients prior to and following stepwise administration of 5, 10, 20, 40, and 80 mg doses. The major endpoint for the study was the achievement of clinical beta blockade (heart rate 50-60 beats/min and 20% rise in treadmill stage I heart rate). Betaxolol produced a decrease in mean angina pectoris frequency from 6.6 ± 1.9 episodes/week with placebo to 0.2 ± 0.5 episode/week during clinical beta blockade (p < 0.00005). Mean treadmill exercise time increased from 3.1 ± 1.7 min with placebo to 7.3 ± 2.3 min with doses sufficient to reduce angina pectoris frequency 75% (p < 0.00005) and to 8.0 ± 2.3 min during clinical beta blockade (p < 0.00005). The mean doses of betaxolol required to produce a 75% decrease in angina pectoris frequency and clinical beta blockade were 12 ± 5 mg (range 5-40 mg) and 28 ± 29 mg (range 5-80 mg) respectively. Mean serum concentrations associated with these clinical endpoints were 23.8 ± 9.7 ng/mL and 59.7 ± 54.0 ng/mL respectively. The results indicate that betaxolol, in widely ranging doses, is highly effective in reducing angina pectoris frequency and improving exercise capacity in patients with stable exertional angina pectoris.

Angiology, Vol. 41, No. 5, 365-376 (1990)
DOI: 10.1177/000331979004100503


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?